KLK3 and posterior cortical atrophy: The combined assessment of certain clinically established criteria, such as PSA and the Gleason score, alongside molecular markers, including driver mutations and gene expression signatures, has been highlighted as putative biomarkers for PCa risk stratification and prognosis [8].